Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trametinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 17/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.37 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trametinib SCHEMBL29363416 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL170938 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL1419085 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL1419395 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL21048481 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL1419392 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL30035834 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL30301264 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL1419017 | 0.98 | MAP2K1 (0.97) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| SCHEMBL26815709 | 0.98 | MAP2K1 (0.96) | MAP2K1MAP2K2ABCB1NOX4PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120051560-A | Methods and compositions for generating human midbrain dopaminergic neurons from neural progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-118765319-A | Induced mature liver cell and preparation method thereof | 清华大学 | 2024-10-11 | — | — | CN | claimed |
| CN-118591620-A | Methods and compositions for generating and maturing human forebrain neural progenitor cells into small albumin positive interneurons | 特雷尔赫德生物系统股份有限公司 | 2024-09-03 | — | — | CN | claimed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117677691-A | Methods and compositions for the generation of human midbrain neural progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-114807035-B | Reproducible differentiation method of clinical grade retinal pigment epithelial cells | (由卫生与公众服务部部长代表的)美利坚合众国 | 2024-02-02 | — | — | CN | claimed |
| CN-116694551-A | Induced mature liver cell and preparation method thereof | 清华大学 | 2023-09-05 | — | — | CN | claimed |
| CN-115803316-A | Pyridone compound and preparation method and application thereof | 深圳晶泰科技有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-115198013-A | Methods and kits for identifying patients for arginine deprivation therapy | 迪瑞药业(成都)有限公司 | 2022-10-18 | — | — | CN | claimed |
| WO-2022086892-A1 | INTERLEUKIN 4 (IL4)-INDUCED GENE 1 INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| CN-114685426-B | Sulfonamide inhibitor, preparation method and application thereof | Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-122055153-A | EGFR inhibitors for treating EGFR exon 20 mutation positive lung cancer | 安塔列斯疗法股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122029161-A | Crystalline forms of PI3K inhibitors and uses thereof | 蝎子疗法股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122028918-A | TRIM7 inhibitors and uses thereof | 沙塔克实验室有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250250540-A1 | METHOD FOR DIFFERENTIATION OF OCULAR CELLS AND USE THEREOF | FUJIFILM Cellular Dynamics, Inc. (US) | 2025-08-07 | — | — | US | disclosed |
| CN-114096280-A | Therapeutic constructs for co-delivery of mitotic kinase inhibitors and immune checkpoint inhibitors | 俄勒冈健康与科学大学 | 2022-02-25 | — | — | CN | disclosed |
| CN-114096274-A | Immunotherapeutic constructs and methods of use thereof | 俄勒冈健康与科学大学 | 2022-02-25 | — | — | CN | disclosed |
| CN-108686221-B | Synergistic antitumor drug | 广州威溶特医药科技有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-114025844-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-215643385-U | Device for direct drug infusion | 基因泰克股份有限公司 | 2022-01-25 | — | — | CN | disclosed |